Pharmacologic Management of Acute Attacks of Migraine and Prevention of Migraine Headache

Snow, Vincenza; Weiss, Kevin B.; Wall, Erika; Mottur‐Pilson, Christel

doi:10.7326/0003-4819-137-10-200211190-00014

Cited by 174 publications

(123 citation statements)

References 103 publications

Supporting

Mentioning

120

Contrasting

Unclassified

Order By: Relevance

“…One explanation for this result is that, despite attempts to control for variation in disease severity, undetected differences remained between the two study groups. Current treatment recommendations typically suggest that prevention be reserved for patients with more debilitating headaches [12,13]. Use of MSAM provided indirect evidence that this recommendation was being followed during the analysis.…”

Section: Discussionmentioning

confidence: 99%

“…One such breakthrough was the expansion of effective choices for daily migraine prevention. While prevention has been shown to reduce the frequency and severity of migraine headaches [12,13], it is unclear whether or not this treatment has an effect on a patient's use of migrainerelated medical services. Cost-effectiveness analysis has suggested that some preventive medications are costeffective, but for only a subset of patients with frequent headaches or comorbid illness [14,15].…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Effect of daily migraine prevention on health care utilisation in an insured patient population

Devine¹,

Hadsall

Cline

et al. 2007

J Headache Pain

View full text Add to dashboard Cite

The economic benefits of daily migraine prevention have been subject to ongoing debate. This study was undertaken to determine if the initiation of prevention had an observable effect on ambulatory health care utilisation when compared to acute migraine treatment alone. Administrative claims data from the Military Health System were used to conduct a retrospective, longitudinal cohort study of 3762 patients with migraine. New users of daily migraine prevention were matched to a reference group of non-users using propensity score methods. This matched sample then was used to evaluate the effect of prevention on ambulatory health care expenditures. The study results showed that exposure to daily migraine prevention led to lower rates of utilisation relative to what new patients would have consumed in the absence of treatment. The results suggest that additional economic benefits could be realised by increasing the appropriate use of daily migraine prevention.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Effect of daily migraine prevention on health care utilisation in an insured patient population

Devine¹,

Hadsall

Cline

et al. 2007

J Headache Pain

View full text Add to dashboard Cite

show abstract

“…1 In addition, manufacturers' dosing recommendations for the 5-HT1 receptor agonists indicate that the safety of treating an average of more than 3 to 4 headaches with these agents in a 30-day period has not been established. [6][7][8][9][10][11][12][13][14] MCOs have reported pharmacy cost savings with programs that impose quantity limits on the triptan medications. [15][16][17] These point-of-service edit programs typically allow for edit overrides after review of clinical information documenting a requirement for doses that exceed program limits.…”

Section: Evaluation Of a Monthly Coverage Maximum (Drug-specific Quanmentioning

confidence: 99%

Evaluation of a Monthly Coverage Maximum (Drug-Specific Quantity Limit) on the 5-HT1 Agonists (Triptans) and Dihydroergotamine Nasal Spray

Hoffman

Mayzell²,

Pedan³

et al. 2003

JMCP

View full text Add to dashboard Cite

“…1 While not an acute treatment, corticosteroids, including intravenous methylprednisolone (IVMP) (15)(16)(17)(18)(19)(20)(21)(22)(23)(24)(25)(26)(27)(28)(29)(30) mg/kg/dose, maximum 1000 mg/day), have been shown to be effective in reducing the rate of headache recurrence. 2 IVMP infusions have been associated with adverse effects including hypotension, hypertension, bradycardia, tachycardia, and some reports of unexplained death.…”

Section: Introductionmentioning

confidence: 99%

Effects of Methylprednisolone Infusions on Vital Signs in Children With Headaches

Heidrich

Greene

Weberding

et al. 2013

The Journal of Pediatric Pharmacology and Therapeutics

View full text Add to dashboard Cite

OBJECTIVES Intravenous methylprednisolone (IVMP) infusions have been associated with adverse cardiovascular effects. Inconsistent monitoring practices in a pediatric hospital led to questions about patient safety and allocation of nursing resources. This study describes vital sign changes in children and monitoring practices related to IVMP. METHODS This retrospective chart review received Institutional Review Board approval. Children aged 5 to 17 years receiving IVMP from January 2006 to January 2009 were included. Seventy-four patients with 94 hospital admissions were evaluated. Data collected included systolic blood pressure, diastolic blood pressure, and heart rate, as well as the time and dosage of IVMP. Frequency of vital sign monitoring as ordered and as performed was described. Interrater reliability was calculated, and descriptive statistics were used in the data analysis. RESULTS At baseline, about half of the patients had vital signs out of normal range for age. After the first dose, vital signs fluctuated, with a majority having greater than 10% changes from baseline as increases, decreases, or both. Time of initial 10% change in vital signs ranged from immediately after the dose to 135.5 hours later. Increased vital sign changes were seen in the older patients and in patients receiving higher doses. Monitoring of vital signs occurred more frequently than was ordered. Only 1 patient had a specific order for monitoring with IVMP. CONCLUSIONS The patients included in this study experienced documented fluctuations in vital signs. A prospective study to evaluate the relationship of IVMP and patient safety will assist in standardizing vital sign monitoring guidelines. INDEX TERMS

show abstract

Pharmacologic Management of Acute Attacks of Migraine and Prevention of Migraine Headache

Cited by 174 publications

References 103 publications

Effect of daily migraine prevention on health care utilisation in an insured patient population

Effect of daily migraine prevention on health care utilisation in an insured patient population

Evaluation of a Monthly Coverage Maximum (Drug-Specific Quantity Limit) on the 5-HT1 Agonists (Triptans) and Dihydroergotamine Nasal Spray

Effects of Methylprednisolone Infusions on Vital Signs in Children With Headaches

Contact Info

Product

Resources

About